Linsitinib is a small-molecule dual insulin-like growth factor-1 receptor (IGF-IR) and insulin receptor (IR) kinase inhibitor. IGF-I receptor (IGF-IR) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies and thus Linsitinib may be a useful anticancer agent.Appearance:White to off-white crystalline solidPurity:≥99% (HPLC, TLC)Solubility:DMSO, 50mg/mlMelting Point:233-237°C